Samuel Klempner, MD
Hematology & Oncology · Los Angeles, CANPI 1134329378
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $144,544 of the $204,471 with a category attached, or 70.7%. It is spread thinly across 27 manufacturers, the largest accounting for just 21.1%. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $1635.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$43K
- AstraZeneca$22K
- Lilly USA, LLC$17K
- Astellas Pharma US Inc$16K
- Foundation Medicine, Inc.$14K
- Astrazeneca UK Limited$13K
- plus $79K from 21 others
Across 164 payments — averaging $5246.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$282K
- Incyte Corporation$208K
- AstraZeneca$196K
- Macrogenics, Inc.$74K
- Regeneron$35K
- GSK$26K
- plus $40K from 6 others
What the payments were for
- Consulting fees$144,54471%
- Speaking & faculty fees$42,20921%
- Travel & lodging$15,3798%
- Food & beverage$2,3401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $43,124 |
| AstraZeneca | 15 | $21,919 |
| Lilly USA, LLC | 11 | $16,583 |
| Astellas Pharma US Inc | 7 | $16,415 |
| Foundation Medicine, Inc. | 12 | $14,380 |
| Astrazeneca UK Limited | 6 | $13,198 |
| Novartis | 4 | $12,730 |
| Sanofi US Services Inc. | 2 | $9,637 |
| E.r. Squibb & Sons, L.L.C. | 12 | $7,808 |
| Eli Lilly | 2 | $6,050 |
| Astellas Pharma Europe Ltd | 5 | $5,989 |
| Eisai Inc. | 2 | $4,774 |
| Daiichi Sankyo Inc. | 4 | $3,970 |
| Sanofi | 4 | $3,872 |
| Servier Bioinnovation | 2 | $3,740 |
| Beigene USA, Inc. | 1 | $3,375 |
| Gilead | 3 | $2,986 |
| Boehringer Ingelheim International GmbH | 1 | $2,960 |
| Amgen | 6 | $2,799 |
| Incyte Corporation | 1 | $2,639 |
| F. Hoffmann-la Roche AG | 1 | $2,280 |
| Taiho Oncology, Inc. | 1 | $1,320 |
| Coherus Oncology, Inc. | 1 | $900 |
| Jazz Pharmaceuticals Inc. | 1 | $837 |
| Seagen Inc. | 1 | $95 |
| Genentech, Inc. | 1 | $62 |
| Beone Medicines USA, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$19,239
- FOUNDATIONFOCUS$14,257
- FOUNDATIONONE CDX$14,257
- FOUNDATIONONE HEME$14,257
- FOUNDATIONONE$14,257
- Vyloy$9,660
- FOUNDATIONACT$8,757
- IMFINZI$8,470
- FOUNDATIONONE LIQUID$5,500
- CYRAMZA$5,449
- LENVIMA$4,740
- ASPARLAS$3,740
- Enhertu$3,425
- TEVIMBRA$3,375
- OPDIVO$2,400
- TECENTRIQ$2,280
- LYTGOBI$1,320
- ZIIHERA$837
How this compares
$204,471 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $9,606 |
| Omeprazole | 20 | $310 |
| Dexamethasone | 13 | $138 |
| Oxycodone Hcl | 12 | $95 |
| Prochlorperazine Maleate | 12 | $91 |
| Prednisone | 15 | $35 |
| Ondansetron Hcl | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.